Embryonic stem-cell research would get a financial boost under a new proposal by the National Institutes of Health. According to the Wall Street Journal, the NIH guidelines expand funding for cell lines derived from surplus human embryos.
According to the National Kidney Foundation, over 26 million Americans suffer from chronic kidney disease (CKD), a progressive condition in which the kidneys allow waste to build up in the blood.
President Obama’s recent reversal of Bush’s policy on embryonic stem cell research reignited the debate over the ethical limits of science. However, as the Wall Street Journal reports, an innovative new technique could potentially reproduce the benefits of embryonic stem cells without the attendant controversy.
Foundation Radiology Group, a provider of diagnostic imaging services to hospitals and medical institutions, announced that it has raised $10 million in the company’s first round of venture funding.
While prosthetic legs have undergone remarkable advances in the past decades, the typical prosthetic arm hasn’t changed much since World War II: an artificial limb with a hook on the end. It’s a less than thrilling prospect for U.S. soldiers returning from Iraq or Afghanistan with amputated arms.
The economic climate may be grim, but biotech banker G. Steven Burrill is looking to the future. The CEO of Burrill and Co. plans to invest $1 billion into Minnesota’s Pine Island biotechnology project and a private equity/venture capital fund.
Big news at ORTHOCON, DeviceSpace reports. The New Jersey-based company, which develops devices that deliver therapeutics to bone, recently announced the appointment of a new CEO and the closing of $25 million in Series B funding.
As Baby Boomers age, the market for arthroplasty, or joint replacement, is expected to grow rapidly in the coming years. Disc Motion Technologies (DMT) of Boca Raton, FL, has pioneered the first total joint replacement technique for the lumbar spine.
Many patients are left humiliated and depressed because of the daily disruptions caused by urinary or fecal incontinence. Vermont company AugmentRX is developing incontinence solutions for the 200 million-plus people worldwide who suffer from this debilitating condition.
A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.
Copyright © 2024 | WordPress Theme by MH Themes